【摘要】 目的 评价标准化疗方案治疗无效时，同期应用化疗和IL-2治疗晚期恶性肿瘤的近期疗效和毒副反应。方法 72例经3～6周期标准方案化疗无效的恶性肿瘤患者作为研究对象，按肿瘤类型、性别、年龄、体质状况配成36对，并随机分入生物化疗组和单纯IL-2组。生物化疗组维持原化疗方案不变，按标准周期进行，并同期应用IL-2 100万u皮下注射，每天1次，每周1～5天，2～4周为1周期，2～3周期评价疗效；单纯IL-2组单独应用IL-2，100万u皮下注射，每天1次，每周1～5天，4周为1个周期，2～3周期评价疗效。结果 生物化疗组36例患者取得较好的疗效，分别为CR 0例，PR 4例，总有效率(CR+PR)为11.1%，治疗前后差异有显著性(P<0.05)。单纯IL-2组的疗效分别为CR 0例，PR 1例，总有效率(CR+PR)为2.8%。两组间差异有显著性(P<0.05)。两组的毒副反应主要表现为发热、骨髓抑制、消化道反应，毒副反应发生率差异无显著性。结论 晚期恶性肿瘤患者在标准化疗方案治疗无效时，保持原化疗方案不变同期应用IL-2可进一步提高疗效，毒副反应无明显加大，且可耐受。

    【关键词】 白细胞介素Ⅱ；生物化疗；多药耐药；肿瘤

    Clinical observation of concomitant biochemotherapy in treatment of advanced malignant tumor interleukin-2 and multidrug resistance in tumor

    SUN Lei,AN Yong-heng.

    Department of Oncology,The People's Hospital of Zhucheng City， Shangdong 262200,China

    【Abstract】 Objective To evaluate the curative effect and toxic and side effect of concomitant chemotherapy and IL-2 to treat advanced stage malignant tumor after failing in standard chemotherapy.Methods Selecting 72 patients with advanced stage malignant tumor as study subjects, who have completed 3～6 cycles of chemotherapy, CR+PR was 0.All subjects were devided into 36 couples by tumor, sex, age and body condition, separated at random into biochemotherapy group and IL-2 group. The biochemotherapy group were treated with chemotherapy plus concomitant low-dose rhIL-2. Treatment consisted of routine chemotherapy regimen just as the previous one, and concomitant with 1×10(6) IU rhIL-2 ih on day1 to day5 every week,take 2～4 weeks as one cycle. Efficacy was evaluated at 2～3 cycles. The IL-2 group were applied with single rhIL-2,1×10(6) IU ih on day1 to day5 every week, take 4 weeks as one cycle. Efficacy was evaluated at 2～3 cycles. Results The biochemotherpy group achieved better efficacy, among them CR was 0, PR were 4 cases,the total effective rate (CR+PR) was 11.1%.There was significant difference between pre- and post-therapy efficacy(P<0.05).Among the IL-2 group CR was 0 ......